Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Korean Center for Disease Control and Prevention | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The period of about a month after the discharge of acute heart failure patients is defined as a transition time. During this period, the patient has a high mortality rate and a readmission rate because the patient is not stabilized. In the United States and Europe, the readmission rate is more than 25% within 30 days, and the mortality rate within 30 days after discharge is three times that of patients with chronic heart failure.
The TRANS-HF is a prospective, randomized, multi-center, controlled study, which enrolls patients with acute heart failure with reduced ejection fraction.
The objective of TRANS-HF is to improve GAI at six months through three interventions: pre-discharge checklist, heart failure education, and telephone monitoring before the first outpatient visit.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention group | Experimental | The intervention group is managed by applying all three types of intervention. |
|
| non-Intervention group | No Intervention | Non-intervention group is managed by conventional heart failure treatment. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Checklist | Other | Checklist of guideline-based treatment before discharge |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Guideline adherence indicator at 6months | the point of Guideline adherence indicator. Definition of GAI strata : Level of guideline-adherent treatment will be measured by guideline adherence indicator (GAI) such as 0/3, 1/3, 2/3, and 3/3. This GAI data will be obtained once after all prescription data has been collected. It will include whether or not prescribed medication of ≥50% of target dose : 0 points for non-prescription in the absence of contra-indications, 0.5 points for use of <50% of target dosage (<100% of target dose for MRA as the majority of patients were treated with ≥50% of target dose of MRA) or 1 point for use in ≥50% of target dosage (target dose for MRA). Non-administration of recommended drugs due to specific contraindications or intolerance will be scored as adherence to guidelines. | 6months |
| Measure | Description | Time Frame |
|---|---|---|
| Guideline adherence indicator at discharge | the point of Guideline adherence indicator. Definition of GAI strata : Level of guideline-adherent treatment will be measured by guideline adherence indicator (GAI) such as 0/3, 1/3, 2/3, and 3/3. This GAI data will be obtained once after all prescription data has been collected. It will include whether or not prescribed medication of ≥50% of target dose : 0 points for non-prescription in the absence of contra-indications, 0.5 points for use of <50% of target dosage (<100% of target dose for MRA as the majority of patients were treated with ≥50% of target dose of MRA) or 1 point for use in ≥50% of target dosage (target dose for MRA). Non-administration of recommended drugs due to specific contraindications or intolerance will be scored as adherence to guidelines. |
Not provided
All consecutive hospitalized adult heart failure patients who fulfill one of 1-3 and satisfy 4-5 simultaneous
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Byung-Su Yoo, MD, PhD | Wonju Severance Christian Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Wonju Severance Christian Hospital, | Wŏnju | Gangwon-do | 26426 | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42089166 | Derived | Son JW, Cho DH, Kim SE, Choi J, Choi DJ, Cho HJ, Lee CJ, Choi JO, Lee SE, Kim EJ, Chung WJ, Youn JC, Bae DH, Park JH, Kim KH, Kim IC, Choi JH, Lee S, Kim H, Yoo BS. Effectiveness of an Intervention to Improve Guideline-Directed Medications for Patients With Acute Heart Failure: A Randomized Clinical Trial. J Am Heart Assoc. 2026 May 19;15(10):e044747. doi: 10.1161/JAHA.125.044747. Epub 2026 May 6. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D057189 | Checklist |
| D004522 | Educational Status |
| ID | Term |
|---|---|
| D003625 | Data Collection |
| D017531 | Health Care Evaluation Mechanisms |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Education |
| Other |
Heart failure education before discharge |
|
| Telephone monitoring | Other | Telephone monitoring after discharge |
|
| 0 day (at discharge) |
| Guideline adherence indicator at 1month | the point of Guideline adherence indicator. Definition of GAI strata : Level of guideline-adherent treatment will be measured by guideline adherence indicator (GAI) such as 0/3, 1/3, 2/3, and 3/3. This GAI data will be obtained once after all prescription data has been collected. It will include whether or not prescribed medication of ≥50% of target dose : 0 points for non-prescription in the absence of contra-indications, 0.5 points for use of <50% of target dosage (<100% of target dose for MRA as the majority of patients were treated with ≥50% of target dose of MRA) or 1 point for use in ≥50% of target dosage (target dose for MRA). Non-administration of recommended drugs due to specific contraindications or intolerance will be scored as adherence to guidelines. | 1month after discharge |
| KCCQ(The Kansas City Cardiomyopathy Questionnaire) at discharge | the score of the Kansas City Cardiomyopathy Questionnaire | 0 day (at discharge) |
| KCCQ(The Kansas City Cardiomyopathy Questionnaire) at 6 months | the score of the Kansas City Cardiomyopathy Questionnaire | 6 months after discharge |
| EQ-5D(The EuroQoL five-dimensional instrument) at discharge | the score of the EuroQoL five-dimensional instrument | 0 day (at discharge) |
| EQ-5D(The EuroQoL five-dimensional instrument) at 6 months | the score of The EuroQoL five-dimensional instrument | 6 months after discharge |
| All-cause death | incidence rate (%) of death from any cause | up to 6 months |
| Heart failure rehospitalization | incidence rate (%) of the first rehospitalization due to heart failure | up to 6 months |
| Cardiovascular death | incidence rate (%) of death due to heart failure, arrhythmia and cerebrovascular event. | up to 6 months |
| Cardiovascular rehospitalization | incidence rate (%) of the first rehospitalization due to heart failure, arrhythmia, and cerebrovascular event. | up to 6 months |
| Composite end-point | incidence rate (%) of all-cause death and the first rehospitalization rehospitalization | up to 6 months |
| D012959 | Socioeconomic Factors |
| D011154 | Population Characteristics |